Alkermes (ALKS)
(Real Time Quote from BATS)
$28.43 USD
+0.56 (2.01%)
Updated Sep 18, 2025 12:54 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALKS 28.43 +0.56(2.01%)
Will ALKS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALKS
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue?
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for ALKS
ALKS forms 50 Day Moving Average Resistance on September 17
Is ALKS building bearish momentum? Lower Bollinger Band Walk shows up after advancing 3.28%
IYH: Healthcare Dashboard For September
ALKS forms NR7 on September 15
Tracking Baker Brothers Portfolio - Q2 2025 Update